Angiotech Pharmaceuticals and Athersys said a Phase I trial showed that MultiStem, their experimental stem cell treatment, proved to be effective in improving cardiac function and was well-tolerated by heart attack patients who were given different dosages. The companies said they plan to conduct trials next year.

Full Story:

Related Summaries